Russia plans to produce 30 million doses of an experimental COVID-19 vaccine domestically this year, with the potential to manufacture a further 170 million doses abroad, the head of the country's sovereign wealth fund said.
The first human trial of the vaccine, a month-long test on 38 people, ended this week. Researchers concluded that it is safe for use and induces an immune response, though the strength of that response is as yet unclear.
A larger Phase III trial involving several thousand people is expected to begin in August, Russian Direct Investment Fund (RDIF) head Kirill Dmitriev.